Adel Nada, GentiBio CEO
In bid for new T cell therapies, Bristol Myers inks deal with Treg player GentiBio
A myriad of rare T cell types has popped on the radar in recent years as companies search for the next generation of T cell therapies. Among those are regulatory T cells, or Tregs, which were at the center of a number of big raises last year.
Now one of those Treg players, GentiBio — which reeled in a $157 million Series A last year — has inked a deal with Bristol Myers Squibb, as the Big Pharma looks to add to its selection of T cell therapies, which currently includes two CAR-Ts.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
